Lire le communiqué de la SARR en pdf SATT CONECTUS
Albupad provides a foundational platform for powering next-generation therapeutics,
medical devices and hybrid drug-device products.
Albupad invented a natural, proprietary biomaterial that leverages the intrinsic qualities of albumin
– including biocompatibility, biodegradability, tumor tropism, and inherent imaging visibility
– while eliminating the need for synthetic targeting ligands , toxic excipients, or added imaging agents.
Beyond its biological and regulatory advantages, the Albupad biomaterial offers exceptional versatility of formulation and tunable forms.
TECHNOLOGY
ALBUPAD technology was developed to produce
the next generation of albumin based materials
Our targeted applications are mainly
drug delivery (human or veterinary use) and tissue engineering
We developed a green approach that allows
the production of materials entirely made of albumin
Lire la vidéo
We are a team of scientists with a strong expertise in the development of drug delivery systems
(formulation, characterization, preclinical testing),
as well as in the fields of biomaterials, encapsulation and vectorization.
You can contact us for any questions by sending an email
OUR LATEST NEWS
Révolutionner la délivrance des médicaments
Lire le document en pdf INSERM Magazine Lire l’article en ligne INSERM Magazine
Albupad dans le Dauphiné
De chercheur à startupper Eya Aloui, CEO de la startup Albupad, présente dans le réseau Bpifrance depuis 2021, a partagé son expérience pour la première fois : « C’est très instructif. Cela permet de diagnostiquer l’écosystème deeptech, de le faire … Read More